Loading
AZD9793 is an experimental T-cell engager from AstraZeneca in phase 2 trials for hepatocellular carcinoma, aimed at Glypican-3.
AZD9793 is a T-cell engager developed by AstraZeneca. Its target is Glypican-3 (the sponsor names GPC3). The sponsor states: AZD9793 is a T-cell-engaging antibody that targets GPC3 on tumour cells, dosed intravenously and subcutaneously in the first-in-human RHEA-1 study, with a focus on hepatocellular carcinoma. ClinicalTrials.gov describes the intervention as: T cell-engaging antibody that targets GPC3 on tumour cells. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in hepatocellular carcinoma. The largest, NCT06795022, plans to enrol 304 participants with primary completion expected 2027-06-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
AZD9793 is a T-cell-engaging antibody that targets GPC3 on tumour cells, dosed intravenously and subcutaneously in the first-in-human RHEA-1 study, with a focus on hepatocellular carcinoma. Connects to Glypican-3.
1.One arm of AZD9793 binds Glypican-3 on the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"AZD9793" OR ABSTRACT:"AZD9793") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about AZD9793, not a curated reading list.
Shares AstraZeneca, Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.